Department of Thyroid and Breast Surgery, The Ninth People's Hospital of Suzhou, Suzhou, China.
Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12224-12231. doi: 10.26355/eurrev_202012_24013.
The aim of this study is to uncover the correlations of the expression of colon cancer associated transcript 2 (CCAT2) in the clinical papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC) specimens with the prognosis and chemoresistance of patients.
The expression level of CCAT2 in the PTC and ATC specimens was determined using Real-Time quantitative Polymerase Chain Reaction (RT-qPCR), and the correlations of CCAT2 expression with the clinical features of patients were detected via χ2 test. Besides, survival analysis was conducted to verify the relation between CCAT2 expression and patients' survival. After knockdown or overexpression of CCAT2, the changes in the proliferation ability of human thyroid carcinoma cells were examined via Cell Counting kit-8 (CCK-8) assay, and the half maximal inhibitory concentration (IC50) values of doxorubicin and cisplatin were measured by methyl thiazolyl tetrazolium (MTT) assay.
According to the χ2-test results, the expression of CCAT2 was notably correlated with the capsular invasion and lymph node metastasis of PTC, and the capsular invasion, tumor size, and lymph node metastasis of ATC. It was discovered through the survival analysis that the expression of CCAT2 was notably associated with the poor prognosis of ATC patients. After knockdown of CCAT2, both the proliferation ability and the IC50 values of doxorubicin and cisplatin substantially declined in human thyroid carcinoma cells. The opposite conditions were found after CCAT2 was overexpressed in human thyroid carcinoma cells.
CCAT2 potentiates the proliferation ability and chemoresistance of cells, promotes the progression of thyroid carcinoma, and hinders the prognosis of ATC.
本研究旨在揭示结肠癌相关转录物 2（CCAT2）在临床甲状腺乳头状癌（PTC）和间变性甲状腺癌（ATC）标本中的表达与患者预后和化疗耐药性的相关性。
采用实时定量聚合酶链反应（RT-qPCR）检测 PTC 和 ATC 标本中 CCAT2 的表达水平，通过卡方检验检测 CCAT2 表达与患者临床特征的相关性。此外，通过生存分析验证 CCAT2 表达与患者生存的关系。敲低或过表达 CCAT2 后，通过细胞计数试剂盒-8（CCK-8）检测人甲状腺癌细胞增殖能力的变化，通过噻唑蓝（MTT）检测多柔比星和顺铂的半数最大抑制浓度（IC50）值。
根据卡方检验结果，CCAT2 的表达与 PTC 的包膜侵犯和淋巴结转移以及 ATC 的包膜侵犯、肿瘤大小和淋巴结转移显著相关。通过生存分析发现，CCAT2 的表达与 ATC 患者的不良预后显著相关。敲低 CCAT2 后，人甲状腺癌细胞的增殖能力和多柔比星和顺铂的 IC50 值显著下降。在人甲状腺癌细胞中过表达 CCAT2 时则发现了相反的情况。
CCAT2 增强了细胞的增殖能力和化疗耐药性，促进了甲状腺癌的进展，阻碍了 ATC 的预后。
